Aprogen Biologics Inc. (KRX:003060)
South Korea · Delayed Price · Currency is KRW 2,095.00
-60.00 (-2.78%)
Aug 12, 2026, 1:44 PM KST
Aprogen Biologics Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 50,727 | 102,540 | 130,793 | 190,684 | 200,481 | 360,706 | |
Market Cap Growth | -58.85% | -21.60% | -31.41% | -4.89% | -44.42% | -31.18% |
Enterprise Value | 296,939 | 318,576 | 176,792 | 383,113 | 209,570 | 302,520 |
Last Close Price | 2155.00 | 7785.00 | 9930.00 | 33059.13 | 57340.49 | 103167.28 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | - | 15.86 | 44.52 |
PS Ratio | 0.65 | 1.40 | 1.94 | 2.18 | 3.08 | 6.39 |
PB Ratio | 0.19 | 0.37 | 0.35 | 0.52 | 0.39 | 0.60 |
P/TBV Ratio | 0.26 | 0.51 | 0.35 | 0.53 | 0.48 | 0.71 |
P/FCF Ratio | - | - | - | - | 8.20 | - |
P/OCF Ratio | - | - | - | - | 7.79 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.81 | 4.35 | 2.62 | 4.39 | 3.22 | 5.36 |
EV/FCF Ratio | - | - | - | - | 8.57 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.83 | 0.82 | 0.41 | 0.49 | 0.26 | 0.00 |
Debt / FCF Ratio | - | - | - | - | 5.51 | - |
Net Debt / Equity Ratio | 0.65 | 0.64 | 0.31 | 0.46 | 0.07 | -0.20 |
Net Debt / EBITDA Ratio | -1.81 | -1.71 | -2.93 | -3.47 | -19.81 | 64.35 |
Net Debt / FCF Ratio | -4.23 | -3.70 | -2.50 | -2.77 | 1.46 | 17.44 |
Asset Turnover | 0.13 | 0.12 | 0.11 | 0.14 | 0.10 | 0.09 |
Inventory Turnover | 1.93 | 1.94 | 1.50 | 1.98 | 1.25 | 3.09 |
Quick Ratio | 0.31 | 0.32 | 0.38 | 0.17 | 0.75 | 15.45 |
Current Ratio | 0.67 | 0.67 | 0.78 | 0.54 | 1.49 | 37.41 |
Return on Equity (ROE) | -42.75% | -51.29% | -28.09% | -26.24% | 2.46% | 1.53% |
Return on Assets (ROA) | -12.02% | -13.04% | -6.20% | -6.94% | -0.40% | -0.40% |
Return on Invested Capital (ROIC) | -25.83% | -25.90% | -11.33% | -13.02% | -0.75% | -0.85% |
Return on Capital Employed (ROCE) | -33.30% | -34.30% | -13.20% | -16.40% | -0.80% | -0.70% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -258.65% | -166.11% | -80.26% | -62.02% | 6.30% | 2.25% |
FCF Yield | -82.44% | -46.67% | -35.37% | -32.38% | 12.19% | -1.95% |
Buyback Yield / Dilution | -24.51% | -57.15% | -99.30% | -56.07% | -1.42% | -25.52% |